{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:53:41Z","timestamp":1770328421737,"version":"3.49.0"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec023\">\n<jats:title>Background<\/jats:title>\n<jats:p>The therapeutic landscape in generalized myasthenia gravis (gMG) has been continuously evolving in recent years, with over five products approved, each with different efficacy, safety, and administration profiles. With the availability of new targeted treatments, physicians are faced with the challenge of therapeutic decision-making tailored to traditional therapeutic goals, individual preferences, and personal experience, seeking optimal disease control with a positive safety profile. In this context of uncertainty and multiple novel choices, this study aims to provide insights into the preferred treatment choices of neurologists managing gMG and to identify demographic, professional or behavioral factors influencing the decision-making process.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec024\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This is a non-interventional, cross-sectional, web-based study involving 150 neurologists treating gMG patients in collaboration with the Spanish Society of Neurology. The primary endpoint will be to assess preferences for different gMG treatment attributes using a conjoint analysis to create hypothetical treatment scenarios. Therapeutic inertia, described as the lack of treatment initiation or intensification when therapeutic goals are not met, will be evaluated as a secondary endpoint through 7 case scenarios simulating real gMG clinical practice situations. Neurologists will also answer a survey composed of demographic, professional, and behavioral characteristics (user resistance behavior, care-related regret, burnout, risk attitude, empathy, work fulfilment, and personality traits) to recognize possible factors influencing decisions.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec025\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The study findings will contribute to better understanding of decision-making in gMG under a changing therapeutic landscape with multiple new targeted options, and will identify which factors have a role in affecting those decisions.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0322168","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T17:31:18Z","timestamp":1745343078000},"page":"e0322168","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing therapeutic decisions in generalized myasthenia gravis: Study protocol"],"prefix":"10.1371","volume":"20","author":[{"given":"Gerardo","family":"Guti\u00e9rrez-Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9582-9230","authenticated-orcid":true,"given":"Roc\u00edo","family":"G\u00f3mez-Ballesteros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3400-1434","authenticated-orcid":true,"given":"Javier","family":"Sotoca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"Ares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Villaverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1058-3169","authenticated-orcid":true,"given":"Virginia","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tha\u00eds","family":"Armangu\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Salas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"D\u00edaz-Ab\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Sarmiento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iratxe","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Maurino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Querol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"5","key":"pone.0322168.ref001","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/WCO.0000000000001196","article-title":"Current drug treatment of myasthenia gravis","volume":"36","author":"F Vanoli","year":"2023","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"pone.0322168.ref002","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"L Dresser","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"pone.0322168.ref003","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/mus.27742","article-title":"The best and worst of times in therapy development for myasthenia gravis","volume":"67","author":"M Benatar","year":"2023","journal-title":"Muscle Nerve"},{"issue":"3","key":"pone.0322168.ref004","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"P Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"12","key":"pone.0322168.ref005","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis","volume":"30","author":"F Sacc\u00e0","year":"2023","journal-title":"Eur J Neurol"},{"key":"pone.0322168.ref006","doi-asserted-by":"crossref","first-page":"17562864231213240","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"H Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"pone.0322168.ref007","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12912-023-01460-0","article-title":"Reasons for resistance to change in nursing: an integrative review","volume":"22","author":"R Cheraghi","year":"2023","journal-title":"BMC Nurs"},{"issue":"5","key":"pone.0322168.ref008","doi-asserted-by":"crossref","first-page":"e0286129","DOI":"10.1371\/journal.pone.0286129","article-title":"Burnout among neurologists caring for patients with cognitive disorders in Spain","volume":"18","author":"J Fortea","year":"2023","journal-title":"PLoS One"},{"issue":"12","key":"pone.0322168.ref009","doi-asserted-by":"crossref","first-page":"e0261050","DOI":"10.1371\/journal.pone.0261050","article-title":"Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain","volume":"16","author":"G Saposnik","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"pone.0322168.ref010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12913-019-3889-4","article-title":"Factors affecting general practitioners\u2019 decisions to adopt new prescription drugs - cohort analyses using Australian longitudinal physician survey data","volume":"19","author":"Y Zhang","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"pone.0322168.ref011","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12020274","article-title":"Conjoint analysis: A research method to study patients\u2019 preferences and personalize care","volume":"12","author":"B Al-Omari","year":"2022","journal-title":"J Pers Med"},{"issue":"4","key":"pone.0322168.ref012","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"JFP Bridges","year":"2011","journal-title":"Value Health"},{"issue":"2","key":"pone.0322168.ref013","article-title":"Assessing pharmacists\u2019 preferences towards efficacy attributes of disease-modifying therapies in relapsing-remitting multiple sclerosis","volume":"8","author":"I Martinez-Lopez","year":"2020","journal-title":"Pharmacy (Basel)"},{"issue":"5","key":"pone.0322168.ref014","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/JNN.0000000000000661","article-title":"Preferences toward attributes of disease-modifying therapies: the role of nurses in multiple sclerosis care","volume":"54","author":"B Del R\u00edo-Mu\u00f1oz","year":"2022","journal-title":"J Neurosci Nurs"},{"issue":"5","key":"pone.0322168.ref015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"V Bril","year":"2023","journal-title":"Lancet Neurol"},{"issue":"7","key":"pone.0322168.ref016","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"J Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5","key":"pone.0322168.ref017","first-page":"EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"T Vu","year":"2022","journal-title":"NEJM Evid"},{"issue":"1","key":"pone.0322168.ref018","first-page":"55","article-title":"Eliciting exploratory patient preference data: a case study in a rare disease","volume":"38","author":"K-A Ho","year":"2024","journal-title":"Pharmaceut Med"},{"issue":"5","key":"pone.0322168.ref019","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Jr Howard JF","year":"2023","journal-title":"Lancet Neurol"},{"issue":"1","key":"pone.0322168.ref020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","article-title":"Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a Qualitative Study","volume":"12","author":"K Jackson","year":"2023","journal-title":"Neurol Ther"},{"issue":"1","key":"pone.0322168.ref021","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mus.27443","article-title":"Identifying a patient-centered outcome measure for a comparative effectiveness treatment trial in myasthenia gravis","volume":"65","author":"P Narayanaswami","year":"2022","journal-title":"Muscle Nerve"},{"issue":"5","key":"pone.0322168.ref022","doi-asserted-by":"crossref","DOI":"10.17161\/rrnmf.v2i5.15806","article-title":"Practice patterns in the management of myasthenia gravis: a cross-sectional survey of neurologists in the United States","volume":"2","author":"V Bril","year":"2021","journal-title":"RRNMF Neuromuscular J"},{"issue":"7","key":"pone.0322168.ref023","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"GI Wolfe","year":"1999","journal-title":"Neurology"},{"issue":"5","key":"pone.0322168.ref024","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: still a relevant outcome measure","volume":"44","author":"MG COMPOSITE AND MG-QOL15 STUDY GROUP","year":"2011","journal-title":"Muscle Nerve"},{"key":"pone.0322168.ref025","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"ME Farrugia","year":"2020","journal-title":"Front Neurol"},{"issue":"1","key":"pone.0322168.ref026","first-page":"4","article-title":"The treatment of myasthenia gravis","volume":"49","author":"M Dellarocca","year":"2024","journal-title":"US Pharmacist"},{"issue":"2","key":"pone.0322168.ref027","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"C Farmakidis","year":"2018","journal-title":"Neurologic Clin"},{"issue":"1","key":"pone.0322168.ref028","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.27966","article-title":"Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU)","volume":"69","author":"MK Hehir","year":"2024","journal-title":"Muscle Nerve"},{"key":"pone.0322168.ref029","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2147\/PPA.S101821","article-title":"Preference for pharmaceutical formulation and treatment process attributes","volume":"10","author":"KD Stewart","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"pone.0322168.ref030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12883-016-0577-4","article-title":"Decision making under uncertainty, therapeutic inertia, and physicians\u2019 risk preferences in the management of multiple sclerosis (DIScUTIR MS)","volume":"16","author":"G Saposnik","year":"2016","journal-title":"BMC Neurol"},{"key":"pone.0322168.ref031","doi-asserted-by":"crossref","first-page":"1341473","DOI":"10.3389\/fneur.2024.1341473","article-title":"Therapeutic inertia in the management of neuromyelitis optica spectrum disorder","volume":"15","author":"\u00c1 Cobo-Calvo","year":"2024","journal-title":"Front Neurol"},{"key":"pone.0322168.ref032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105838","article-title":"Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?","volume":"90","author":"G Saposnik","year":"2024","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1","key":"pone.0322168.ref033","first-page":"327","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"70","author":"A Jaretzki","year":"2000","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"pone.0322168.ref034","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s13760-022-02162-1","article-title":"Minimal symptom expression achievement over time in generalized myasthenia gravis","volume":"123","author":"A Uzawa","year":"2023","journal-title":"Acta Neurol Belg"},{"issue":"7","key":"pone.0322168.ref035","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","article-title":"\u2018Minimal symptom expression\u2019 in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"J Vissing","year":"2020","journal-title":"J Neurol"},{"key":"pone.0322168.ref036","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/PPA.S124192","article-title":"Herding: a new phenomenon affecting medical decision-making in multiple sclerosis care? Lessons learned from DIScUTIR MS","volume":"11","author":"G Saposnik","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"pone.0322168.ref037","first-page":"567-82","article-title":"Investigating user resistance to information systems implementation: a status quo bias perspective","volume":"33","year":"2009","journal-title":"MIS Quarterly"},{"issue":"1","key":"pone.0322168.ref038","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12911-021-01581-z","article-title":"Factors associated with nurses\u2019 user resistance to change of electronic health record systems","volume":"21","author":"Y Cho","year":"2021","journal-title":"BMC Med Inform Decis Mak"},{"issue":"3","key":"pone.0322168.ref039","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MLR.0b013e318280f02c","article-title":"Validation of a 10-item care-related regret intensity scale (RIS-10) for health care professionals","volume":"51","author":"DS Courvoisier","year":"2013","journal-title":"Med Care"},{"issue":"5","key":"pone.0322168.ref040","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11606-014-3112-6","article-title":"Using a single item to measure burnout in primary care staff: a psychometric evaluation","volume":"30","author":"ED Dolan","year":"2015","journal-title":"J Gen Intern Med"},{"issue":"5","key":"pone.0322168.ref041","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10459-018-9839-9","article-title":"The Jefferson Scale of Empathy: a nationwide study of measurement properties, underlying components, latent variable structure, and national norms in medical students","volume":"23","author":"M Hojat","year":"2018","journal-title":"Adv Health Sci Educ Theory Pract"},{"issue":"4","key":"pone.0322168.ref042","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/0013164405282471","article-title":"The measurement of work engagement with a short questionnaire","volume":"66","author":"WB Schaufeli","year":"2006","journal-title":"Educ Psychol Measure"},{"issue":"1","key":"pone.0322168.ref043","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jrp.2006.02.001","article-title":"Measuring personality in one minute or less: A 10-item short version of the big five inventory in English and German","volume":"41","author":"B Rammstedt","year":"2007","journal-title":"J Res Personal"},{"issue":"1","key":"pone.0322168.ref044","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00420-021-01782-z","article-title":"Burnout prevalence among European physicians: a systematic review and meta-analysis","volume":"95","author":"C Hiver","year":"2022","journal-title":"Int Arch Occup Environ Health"},{"key":"pone.0322168.ref045","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2147\/PPA.S143958","article-title":"Aversion to ambiguity and willingness to take risks affect therapeutic decisions in managing atrial fibrillation for stroke prevention: results of a pilot study in family physicians","volume":"11","author":"S Raptis","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"pone.0322168.ref046","doi-asserted-by":"crossref","first-page":"e0267172","DOI":"10.1371\/journal.pone.0267172","article-title":"Medical empathy in medical students in Madrid: A proposal for empathy level cut-off points for Spain","volume":"17","author":"JM Blanco Canseco","year":"2022","journal-title":"PLoS One"},{"issue":"10","key":"pone.0322168.ref047","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1007\/s11606-020-06467-w","article-title":"Impact of physicians\u2019 personalities and behavioral traits on treatment-related decision-making for elderly acute myeloid leukemia","volume":"36","author":"X Wu","year":"2021","journal-title":"J Gen Intern Med"},{"key":"pone.0322168.ref048","doi-asserted-by":"crossref","DOI":"10.1002\/9781118625590","volume-title":"Applied Regression Analysis","author":"NR Draper","year":"1998"},{"issue":"12","key":"pone.0322168.ref049","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"JF Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"8","key":"pone.0322168.ref050","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"A Meisel","year":"2023","journal-title":"J Neurol"},{"key":"pone.0322168.ref051","doi-asserted-by":"crossref","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Jr Howard JF","year":"2024","journal-title":"Front Neurol"},{"issue":"4","key":"pone.0322168.ref052","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/mus.28038","article-title":"How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis?","volume":"69","author":"KG Gwathmey","year":"2024","journal-title":"Muscle Nerve"},{"issue":"6","key":"pone.0322168.ref053","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1007\/s00415-021-10902-1","article-title":"Causes of symptom dissatisfaction in patients with generalized myasthenia gravis","volume":"269","author":"L Andersen","year":"2022","journal-title":"J Neurol"},{"issue":"8","key":"pone.0322168.ref054","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"S Brauner","year":"2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"pone.0322168.ref055","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12325-023-02704-w","article-title":"The burden patients with myasthenia gravis experience in terms of breathing, fatigue, sleep, mental health, discomfort and usual activities in comparison to the general population","volume":"41","author":"S Dewilde","year":"2024","journal-title":"Adv Ther"},{"issue":"7","key":"pone.0322168.ref056","doi-asserted-by":"crossref","first-page":"e16280","DOI":"10.1111\/ene.16280","article-title":"Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis","volume":"31","author":"A Meisel","year":"2024","journal-title":"Eur J Neurol"},{"issue":"14","key":"pone.0322168.ref057","doi-asserted-by":"crossref","first-page":"e1382","DOI":"10.1212\/WNL.0000000000012604","article-title":"Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG Study","volume":"97","author":"M Petersson","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"pone.0322168.ref058","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","article-title":"Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm","volume":"31","author":"G Giovannoni","year":"2018","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"pone.0322168.ref059","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"A He","year":"2020","journal-title":"Lancet Neurol"},{"issue":"1","key":"pone.0322168.ref060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management","volume":"271","author":"T K\u00fcmpfel","year":"2024","journal-title":"J Neurol"},{"issue":"4","key":"pone.0322168.ref061","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/mus.27791","article-title":"Treatment patterns in myasthenia gravis: A United States health claims analysis","volume":"67","author":"M Mahic","year":"2023","journal-title":"Muscle Nerve"},{"issue":"7","key":"pone.0322168.ref062","doi-asserted-by":"crossref","first-page":"e197093","DOI":"10.1001\/jamanetworkopen.2019.7093","article-title":"Comparison of physician therapeutic inertia for management of patients with multiple sclerosis in Canada, Argentina, Chile, and Spain","volume":"2","author":"N Almusalam","year":"2019","journal-title":"JAMA Netw Open"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0322168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T17:31:29Z","timestamp":1745343089000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0322168"}},"subtitle":[],"editor":[{"given":"Aldrin V.","family":"Gomes","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":62,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0322168","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]}}}